Jennifer L. Taubert Sells 59,397 Shares of Johnson & Johnson (NYSE:JNJ) Stock

Johnson & Johnson (NYSE:JNJGet Free Report) EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a filing with the SEC, which is available through this link.

Johnson & Johnson Stock Up 0.7 %

Johnson & Johnson stock opened at $157.87 on Tuesday. The firm has a market cap of $380.04 billion, a price-to-earnings ratio of 11.43, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The business’s 50-day moving average price is $158.18 and its 200 day moving average price is $158.62. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.28 by $0.01. The firm had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. Johnson & Johnson’s revenue for the quarter was down 9.7% compared to the same quarter last year. During the same period last year, the company earned $2.35 earnings per share. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be issued a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 3.02%. The ex-dividend date of this dividend is Friday, February 16th. Johnson & Johnson’s payout ratio is currently 34.47%.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Tuesday, February 6th. TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, November 17th. Morgan Stanley reduced their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 24th. Raymond James raised their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Finally, UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $167.00 to $180.00 in a research note on Friday, December 1st. Eight equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $176.14.

Read Our Latest Research Report on Johnson & Johnson

Institutional Trading of Johnson & Johnson

Institutional investors have recently bought and sold shares of the business. Hibernia Wealth Partners LLC acquired a new stake in Johnson & Johnson in the third quarter valued at approximately $27,000. FNY Investment Advisers LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth approximately $37,000. Tower View Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 165 shares during the last quarter. Keener Financial Planning LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $40,000. Finally, WFA Asset Management Corp boosted its stake in shares of Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 97 shares during the last quarter. 68.40% of the stock is owned by institutional investors and hedge funds.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Articles

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.